If the FDA limited dosages to two treatments inste

If the FDA limited dosages to two treatments instead of the four requested by CytoDyn, wouldn't they state that in their reasoning for not going along with the request and wouldn't they advise CytroDyn of the decision? I don't trust the FDA as far as I could throw their building but I don't see them sacrificing efficacy or determining efficacy in larger doses because of limited supply, if they truly wanted to get leronlimab to market. The supply would be addressed through OWS funding to get it done, don't ya think? Just like with limited vaxxes available, they were given to the more vulnerable populations first, until supplies allowed them to expand. Similarly, wouldn't LL be provided for the critical population first, severe next, etc. until the supplies were able to fill the need? I still lean more to the concept that it's being held back by BP influence and integration into the corrupt FDA that's holding us back. Just like the banking industry was never held accountable for their roles in the 07-08 crash because the Treasury Dept was and is so heavily infiltrated by Goldman Sachs (among other banks) reps, BP plays influence games in the FDA without repercussions. We will see who approves leronlimab first and I'd guess it's going to be someone outside the heavy influence of the US FDA.